Agouron Pharmaceuticals, Inc.

Pfizer Corporation

Pfizer Products Inc.

Susan Elizabeth Kephart

Siegfried Heinz Reich

Michael Brennan Wallace

Indrawan James McAlpine

Ted Michael Bleckman

William Henry Romines, Iii

Chuangxing Guo

Mary Catherine Johnson

Peter Scott Dragovich

Stephen Evan Webber

Jingrong Jean Cui

Robert Steven Kania

Cynthia Louise Palmer

Yufeng Hong

Haitao Li

Judith Gail Deal

Junhu Zhang

Ru Zhou

Jayashree Tikhe

Thomas Jay Prins

Theodore Otto Johnson, Jr

Maria Angelica Linton

Mason Alan Pairish

Liming Dong

Anle Yang

Danlin Gu

Yuanjin Rui

Junhun Zhang

Jayashree Girish Tikhe

Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4. 

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

The present invention is directed to compounds of Formula (I), and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.

Pyrazole compounds as RAF inhibitors

Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis

Nonpeptide benzamide-containing inhibitors of human rhinovirus (HRV) 3C protease are described.

Substituted benzamide inhibitors of rhinovirus 3C protease

Growing community of inventors

San Diego, CA, United States of America

Susan Elizabeth Kephart